- Home
- Daily Diary
- Asset Class
- Sector
- Latest
- Author
- Street Notes
- TheStreet
- Switch to
-0.66| Last Update: 05/20/13 - 4:02 PM EDT |
| Volume: 798,981 |
| YTD Performance: 30.17% |
| Open: $101.61 |
| Previous Close: $101.78 |
| 52 Week Range: $71.56 - $102.42 |
| Oustanding Shares: 194,251,157 |
| Market Cap: 19,770,882,759 |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Qtr (06/13) | Qtr (09/13) | FY (09/13) | FY (09/14) | |
|---|---|---|---|---|
| Average Estimate | $1.48 | $1.52 | $5.74 | $6.26 |
| Number of Analysts | 13 | 12 | 16 | 13 |
| High Estimate | $1.53 | $1.54 | $5.77 | $6.40 |
| Low Estimate | $1.46 | $1.50 | $5.73 | $6.19 |
| Prior Year | $1.52 | $1.42 | $5.37 | $5.74 |
| Growth Rate (Year over Year) | -2.73% | 7.34% | 6.96% | 9.04% |
Outperformance by safe sectors often signals trouble, but not always.
Portfolio Mgr. David Peltier uncovers a low-dollar healthcare stock with big growth potential.
This high-quality name seems ready for another sizable climb.
Becton Dickinson downgraded at Leerink BDX was downgraded to Market Perform, Leerink Swann said. Valuation call, based on an $80 price target.
Becton Dickinson downgraded at JP MorganBDX was downgraded from Neutral to Underweight, JP Morgan said. $72 price target. Company is facing lower end-market demand.
Becton Dickinson’s P/E ratio is far below the 10-year median, and its payout has become quite generous.
At least three Fibonacci time cycles support a bullish stance against this recent low.
This surgical-products name has proven itself recession-resistant, and stands to make you money.
Traders awaited Greek debt-related news, testimony from Bernanke and some high-profile earnings reports.